Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Downgrades Exelon to Sector Weight

Keybanc analyst Sophie Karp downgrades Exelon (NASDAQ:EXC) from Overweight to Sector Weight.
byBenzinga Newsdesk
October 20, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Keybanc analyst Sophie Karp downgrades Exelon (NASDAQ:EXC) from Overweight to Sector Weight.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca, Merck Provided Update on US Regulatory Priority Review of Lynparza in Combination With Abiraterone in Metastatic Castration-resistant Prostate Cancer

By Charles Gross
December 15, 6:04 AM
AstraZeneca and MSD today announced that the US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend the Prescription Drug User Fee Act (PDUFA) date by three months to provide further time for a full review of the supplementary new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of metastati

AZN